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Abstract
Background: Prolonged hospital stay before surgery is a risk for colonization with antibiotic-resistant
microorganisms and possible antibiotic-resistant surgical site infections (SSI), which lacks acknowledgement in
international guidelines for perioperative antibiotic prophylaxis.
Method: Retrospective cohort study focusing on prophylaxis-resistant SSI in adult orthopedic implant patients; with
emphasis on length of hospital stay prior to the index surgery.
Results: We enrolled 611 cases of SSI (median age, 65 years; 241 females and 161 immune-suppressed) in four
large implant groups: arthroplasties (n = 309), plates (n = 127), spondylodeses (n = 31), and nails (n = 46). The
causative pathogen was resistant to the perioperative antibiotic prophylaxis regimen in 307 cases (307/611; 50%),
but the length of pre-surgical hospitalization did not influence the incidences of prophylaxis-resistant SSIs. These
incidences were (107/211;51%) for the admission day, (170/345;49%) within 10 days of delay, (19/35;54%) between
10 and 20 days, and (11/20; 55%) beyond 20 days of hospital stay before surgery. The corresponding incidences of
methicillin-resistant staphylococci were 13%, 14%, 17%, and 5%, respectively. In adjusted group comparisons, the
length of prior hospital stay was equally unrelated to future prophylaxis-resistant SSI (odds ratio 1.0, 95% confidence
interval 0.99–1.01).
Conclusions: In our retrospective cohort of orthopedic implant SSI, the length of pre-surgical hospital stay was
unrelated to the incidence of prophylaxis-resistant pathogens.
Keywords: Perioperative antibiotic prophylaxis, Implant orthopedic surgery, Length of hospital stay, Surgical site
infections
Background
Prolonged hospital stay before orthopedic surgery is a
potential risk for acquisition of antibiotic-resistant mi-
croorganisms [1]. Thus in case of delayed surgery and
surgical site infections (SSI) [2], the SSI might be
multi-resistant or resistant to the perioperative antibiotic
prophylaxis that was administered during the index op-
eration. For example in our hospital, lengthening of hospital
stay by one additional day was associated with a 5%
increment of new MRSA carriage [1]. Moreover,
prophylaxis-resistant germs may remain undetected except
for outbreak situations or scientific studies [3]. This possible
threat not only concerns methicillin-resistant Staphylococcus
aureus (MRSA) [2, 3], but also methicillin-resistant
coagulase-negative staphylococci [4], cephalosporin-resistant
enterococci [5], non-fermenting Gram-negative rods [6] or
extended-spectrum β-lactamase (ESBL) producing rods [7].
These pathogen groups all escape to standard prophylaxis
with first-and second generation cephalosporins [2]. Espe-
cially, implant-related orthopedic surgery [8] is prone to SSI
by methicillin-resistant staphylococci [4].
Many colleagues administer vancomycin or other
broad-spectrum agents as prophylaxis, alone or in com-
bination, for patients with long hospital stays (personal
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communication). There are no data supporting this prac-
tice. National [9] and international [10] guidelines and
consensus meetings [11] do not provide robust evidence
on the choice of the prophylactic agent upon the length
of pre-surgical stay. Indeed, international experts unani-
mously advocate single-dose cephalosporins or vanco-
mycin for any orthopedic procedures [9–12].
In this retrospective cohort analysis, we specifically link
the duration of pre-surgical hospital stay to the antibiotic
resistance profile of orthopedic implant-related SSIs. We
do not compute SSI risks or report treatment successes
that we already have published elsewhere [13–15].
Methods
The Geneva University Hospitals is a tertiary center with a
long tradition of clinical research regarding prevention of
orthopedic implant-related infections [8]. The most recent
prevalence of methicillin-resistant Staphylococcus aureus
(MRSA) and methicillin-resistant coagulase-negative
staphylococci among the clinical isolates in the orthopedic
service were1% [13] and 75% [4, 16], respectively. The hos-
pital recommends a single intravenous dose of pre-operative
cefuroxime 1.5 g as standard prophylaxis in orthopedic sur-
gery and traumatology. Only for cases with convincing
history of penicillin allergy [17] or past/present MRSA car-
riage [3], we recommend one dose of vancomycin 1 g intra-
venously. Discipline regarding these recommendations is
very good, with only maximal 5–10% deviations according
to the last control assessments. We currently lack a univ
ersal policy for searching and decolonizing S. aureus body
carriage before surgery. Positive urinary or anal carriage of
ESBL [7] does not alter our recommendations for ortho-
pedic surgery. If surgery lasts for more than 4 h, prophylaxis
is repeated. In selected cases, surgeons may continue it up
to 24 h; except for open fractures with longer durations of
preemptive treatment [18]. Since 2016, the standard dose
was doubled for obese patients with more than 100 kg
weight [19]. In selected cases, surgeons also implement
arthroplasties with or without aminoglycoside-containing
cement.
For the actual study, we used a composite database (Eth-
ical Committee no. 13–178, 08–057 [13], 08–061 [20],
and 14–198), including all adult patients with orthopedic
implant SSI [8] and a minimal follow-up of two years [1].
We excluded cases that were amputated [21], orthopedic
surgery cases without implants, community-acquired in-
fections, recurrent episodes of the same infection and all
patients necessitating actual or recent systemic antibiotic
administration during the last 2 weeks. Our SSI definitions
were based on the Center of Disease Control standards
[22]. Basically, any infection within 1 year of implantation
was a SSI, unless proven otherwise; e.g. by clear evidence
of a hematogenous [23] or lymphogenous origins [24]. We
defined hospital stay as a hospitalization in acute care
settings. Consequently, we considered long-term care fa-
cilities not as hospitals. We collected several microbio-
logical samples from pus or deep intraoperative tissues,
and ignored results of superficial specimens or of a sinus
tract. The microbiology laboratory processed all speci-
mens according to Clinical and Laboratory Standard’s In-
stitute recommendations [25], before switching to the
EUCAST criteria (European Committee) in 2014 [26].
Statistical analyses
Our primary objective was to assess the association be-
tween the length of prior hospital stay to future SSIs that
were resistant to standard antibiotic prophylaxis (cefurox-
ime or vancomycin). We performed group comparisons
using the Pearson-χ 2 or the Wilcoxon-ranksum-test. An
unmatched multivariate logistic regression analysis
determined associations with the outcome “SSI resistant
to standard prophylaxis”. We introduced independent var-
iables with a p value ≤0.05 in the univariate analysis
stepwise into the multivariate analysis, except for length of
prior hospital stay, which we forced into the final model.
We arbitrarily categorized the length of hospital stay indi-
vidually for the days 0, 1, 2, 3, 4, for the groups between 5
and 9 days, 10–20 days, and more than 20 days; and
plotted them against the occurrence of resistant SSIs. We
used STATA software (9.0, STATA™, USA) and considered
p values ≤0.05 (two-tailed) as significant.
Results
We included 611 orthopedic SSI cases meeting our
study criteria (among 611 patients, 241 females (39%)
and including 161 immune-suppressed persons (27%):
diabetes mellitus (n = 73), active cancer (40), severe
chronic alcoholism (25), medicamentous immune-sup-
pression (20), cirrhosis CHILD C (11), dialysis (4),
solid organ transplantation (1), or a combination of
different immune-suppressed states. Upon diagnosis,
the median age of the patients was 65 years and the
median serum C-reactive protein levels were 83 mg/L.
The presence of soft-tissue abscesses and bacteremia
complicated the infections in 73 (12%) and 98 (16%)
episodes, respectively. The infected implants were:
arthroplasties (n = 309), plates (127), spondylodeses
(31) [27], nails (46) [15], and various others (98). In
25 episodes, the infection occurred in the foot. Our
laboratory detected 84 different microbiological con-
stellations with the five most frequently identified
pathogens being Staphylococcus aureus (n = 166),
streptococci (46), Gram-negatives [6] (140; with 80
non-fermenters including 42 Pseudomonas aeruginosa
cases, and 24 anaerobes [28]), enterococci [5] (33), S.
lugdunenssis [16] (9), and skin commensals (134). In
100 cases, SSI were polymicrobial and in 35 cases
culture-negative [29].
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Associations with previous hospital stay
Overall, 556 (90%) implant surgeries with subsequent SSI
were performed within 10 days after admission, 35 between
10 to 20 days, and 20 after 20 days since admission. For-
mally, the study population was already hospitalized during
a median delay of 1 day (range, 0–178 d, interquartile
range, 0–3 d) before the index surgery, and 44 patients had
previously known MRSA carriage [3]. The prophylactic reg-
imens followed the institutional standards for the majority
of cases, but we detected the following deviations: several
doses of cefuroxime (n = 30), use of ciprofloxacin (1),
amoxicillin/clavulanic acid (1), clindamycin (1), and cefazo-
lin (1). Overall, 36 patients received vancomycin, of which
28 episodes because of previous positive MRSA carriage in
the past, and 8 probably because of presumed betalactam
allergy or betalactam intolerance of various nature. In con-
trast, 16 former MRSA carriers lacked vancomycin for
which the reasons were unknown. In 33 episodes (5%), we
ignored the agent of prophylaxis, which was classified as
“usual” according to the records.
Overall, the causative pathogen of future SSI was resist-
ant to prior prophylaxis in 307 cases (307/611; 50%)
(Table 1), but lacked association to previous length of
pre-surgical hospitalization. The incidences of resistant
pathogens were (107/211; 51%) for surgeries performed
on the day of admission, (89/200; 45%) on Day 1, (24/41;
59%) on Day 2, (25/40; 63%) on Day 3, (9/17; 53%) on Day
4, (18/39; 46%) between 5 and 9 days since admission,
(24/43; 56%) between 10 and 20 days, and (11/20; 55%)
beyond 20 days after admission. The corresponding inci-
dences of SSI due to methicillin-resistant staphylococci
were 13% (27/211), 10% (19/200), 24% (10/41), 20% (8/
40), 24% (4/17), 13% (5/39), 21% (9/43) and 5% (1/20), re-
spectively. Figure 1 display the proportion graphically and
denies the existent of a threshold in the number of days of
hospital stay prior to surgery and subsequent
prophylaxis-resistant and methicillin-resistant SSIs. The
proportion of aminoglycoside-resistant SSI (that we com-
puted because of possible cemented arthroplasty) was very
low (3 of 611 cases; 1%). A (past) history of MRSA and
lack of vancomycin prophylaxis was the only variable re-
lated to multi-resistant SSI.
Multivariate adjustment
In view of the considerable case-mix, we performed an ad-
justed logistic regression analysis. Here, the length of prior
hospital stay was equally unrelated to prophylaxis-resistant
SSI as a continuous variable (odds ratio 1.0, 95% confidence
interval 0.99–1.01) or when breaking down to various strat-
ifications (Table 2). Also, in this regression analysis, and
unlike the former crude group comparison, immune-sup-
pression lacked associations with prophylaxis-resistant SSI.
The goodness-of-fit testing of our final model was
non-significant (p = 0.31).
Discussion
In our cohort of orthopedic implant infections among
adult patients, the length of hospital stay before the
index surgery (implantation) was unrelated to the risk of
future SSI due to prophylaxis-resistant pathogens such
as methicillin-resistant staphylococci [4, 13]. Therefore,
we argue against the broadening of the antibiotic
prophylaxis with second-generation cephalosporins to-
wards combinations that include more Gram-positive or
Table 1 Comparisons of demographic and clinical variables of adult orthopaedic implant patients with future surgical site infections
resistant to the prophylactic regimen of the index surgery versus prophylaxis-susceptible surgical site implant infections
Susceptible to prior prophylaxis Resistant to prior prophylaxis
Total n = 611 n = 304 p value* n = 307
Female sex 118 (39%) 0.752 123 (40%)
Age (median) 67 years 0.097 62 years
Past history of MRSAb body carriage 12 (4%) 0.002 32 (10%)
Immune suppressiona 91 (30%) 0.030 70 (23%)
- diabetes mellitus 45 (15%) 0.045 28 (9%)
Shoulder implants 12 (4%) 0.235 7 (2%)
Arthroplasties 147 (48%) 0.275 162 (53%)
Spondylodeses 14 (5%) 0.600 17 (6%)
Plates 66 (22%) 0.575 61 (20%)
Intramedullary nails 20 (7%) 0.376 26 (8%)
Foot osteosyntheses 15 (5%) 0.295 10 (3%)
Duration of prior hospital stay (median) 1 day (range, 0–178 d) 0.408 1 day (range, 0–68 d)
*Significant p values ≤0.05 are displayed in bold and italic
aImmune suppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, or active cancer
bMethicillin-resistant Staphylococcus aureus
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Gram-negative coverage. One might argue, whether
the study question is of importance. International
recommendations are clear and do not recommend
this [1, 2]. And yet, according to our experience,
many surgeons or physicians often broaden the
prophylaxis against official recommendations. Regard-
ing prophylactic issues, our center shows high com-
pliance and the study population is homogenous.
Hence, we could easily perform tour study by avoid-
ing major confounding and substantial interactions,
making the interpretations more difficult.
In the literature, many research groups investigated the
influence of a delay between admission and surgery with
the occurrence of subsequent infection and its pathogen
profile. However, these studies concerned open fractures,
with time delays ranging from 0 to 24 h [18]. We found
only one study specifically linking longer hospitalization
delays with healthcare-associated infections [30]. In this
study from Brazil, patients with nosocomial infections due
to MSSA (not only orthopedic implants) revealed a me-
dian delay of prior hospital stay of 9 days, compared to
MRSA infections with a past median delay of 18 days [30].
Fig. 1 Proportions of future resistant pathogens to standard prophylaxis (vertical axis) according to the delay between admission and the index
implant surgery (horizontal axis). The corresponding trend lines are almost horizontal
Table 2 Univariate and multivariate analyses of factors potentially related to antibiotic prophylaxis-resistant surgical site infections
(Logistic regression analysis; results expressed as odds ratios with 95% confidence intervals)
Total n = 611 Univariate analysis Multivariate analysis
Female sex 1.0, 0.7–1.4 n.d.
Age 1.0, 1.0–1.0 1.0, 1.0–1.0
Past history of MRSAb body carriage 1.3, 1.1–2.9 1.4, 1.1–3.3
Immune suppressiona 0.7, 0.5–1.1 n.d.
- Diabetes mellitus 0.7, 0.4–1.2 n.d.
Shoulder implants 0.5, 0.2–1.5 n.d.
Arthroplasties 1.1, 0.8–1.8 1.2, 0.8–1.9
Spondylodeses 1.4, 0.7–2.9 1.4, 0.6–3.1
Plates 1.0, 0.6–1.5 n.d.
Intramedullary nails 1.2, 0.6–2.3 1.3, 0.6–2.6
Foot osteosyntheses 0.7, 0.3–1.6 0.8, 0.3–1.9
Duration of prior hospital stay 1.0, 1.0–1.0 1.0, 1.0–1.0
- 10–20 days compared to ≤10 days 1.1, 0.5–2.4 1.2, 0.5–2.5
- ≥ 20 days compared to ≤10 days 1.0, 0.6–1.7 1.1, 0.4–3.3
n d. = not done
*Statistically significant results are displayed in bold and italic
aImmune suppression = diabetes mellitus, corticosteroid medication, organ transplantation, cirrhosis CHILD C, dialysis, or active cancer
bMethicillin-resistant Staphylococcus aureus
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In contrast, the literature is full of opinion papers and
retrospective studies investigating the possibility of better
outcomes with broader prophylaxis. The propositions of
the authors differ from one paper to another and focus on
different strategies which are: continuing the prophylaxis
beyond a single dose [31, 32], augmenting of doses [19],
combining with local prophylaxis [33, 34] (especially local
vancomycin in spine surgery [35]), double prophylaxis
[36] against Gram-negative [37], Gram-positive [38, 39],
methicillin-resistant strains [4] and anaerobes [28], or by
investigating the performance of universal glycopeptid
prophylaxis [40–42]. In summary, the majority of these
enhancements failed to reduce SSI risk, at least not in
orthopedic surgery [34, 39–42]. Exceptions remain rare
[32, 37], very specific and often not reproducible by other
research groups [12, 31, 36]. Branch-Elliman et al. esti-
mated that the number of orthopedic cases needed to pre-
vent one Gram-positive SSI with vancomycin would be
1:53 for known MRSA carriers, compared to 1:176 for un-
known carriers [39]. Also, concomitant colonization with
MRSA does not always protect from colonization by sus-
ceptible S. aureus (MSSA) strains [1].
Broader antibiotic prophylaxis can be harmful, especially
with prophylactic aminoglycosides against Gram-negative
pathogens [38, 39]. Numerous studies reported transient
kidney injuries by aminoglycosides [39] or combined
vancomycin prophylaxis [12] in orthopedic surgery. The
risk for antibiotic-resistant organisms seems to be negli-
gible [35]. Walker et al. reported that following a change
in prophylaxis (from floxacillin & gentamycin to amoxicil-
lin/clavulanic acid), they witnessed a 63% decrease in post-
operative renal insufficiencies [43]. In 2009, Scotland
issued a target to reduce Clostridium difficile outbreaks.
Consequently, hospitals changed prophylaxis from a ceph-
alosporin to gentamicin-containing regimens (4 mg/kg),
resulting in a 94% increase in kidney injuries [38].
Besides the fact that our study is retrospective, it has
several limitations. First, we excluded already infected
cases. Hence, we can only address the risk of
prophylaxis-resistant SSI, but we cannot compare between
infected and non-infected populations, or with patients
who were under systemic antibiotic selection for any rea-
son. Second, our orthopedic service has no policy of
pre-surgical S. aureus [2] decolonization. Such a strategy
might alter the association between the length of hospital
stay and the patterns of subsequent SSI. Third, we assume
like many other colleagues that most SSIs origin in the op-
erating theatre [2], and that the length of hospital stay is a
surrogate of nosocomial acquisitions of resistant patho-
gens. In our daily clinical practice, we usually neglect to
assess individual colonization throughout the hospital
stay. This assumption might not be granted. Studies from
Sweden suggest a mounting colonization pressure by
methicillin-resistant staphylococci after two to three days
[4] post-admission, and ESBL acquisitions in orthopedic
wards has also been demonstrated [7], i.e. during wound
care or wound breakdowns. Regarding these ward-born
SSIs, the perioperative antibiotic prophylaxis during the
index surgery would naturally lack influence; which we
equally cannot control for in our retrospective analysis.
Fourth, in our tertiary center, we use cefuroxime as stand-
ard antibiotic prophylaxis for many surgical disciplines, in-
stead of cefazolin, which is another recommended agent
in most guidelines for orthopedic surgeries. Most experts
would agree that the difference and ecological impact be-
tween the two second-generation cephalosporins would
be minimal, as they are close molecules in terms of clinical
spectrum and efficacy. Although we cannot formally pro-
nounce on the hypothetical results of our study performed
under cefazolin, we nevertheless would expect the same
results. Fifth, most of our patients had surgery within few
days since admission, with a median delay of only 1 day.
From a microbiological point of view, it seems rather un-
likely that such a short hospitalization changes
colonization with antibiotic-resistant germs. Nevertheless,
we intended to study real-life conditions without selection
biases. Theoretically, we could have performed a study
only with those patients operated after 1 week of hospital
stay or longer. This would, however, introduce a major
bias and a very small and too specific study population,
which we avoided. Sixth, many our implant infections
were due to coagulase-negative staphylococci and other
skin commensals. Usually, these bacteria are often
regarded as contaminants. In our study, all bacterial re-
sults stem from several deep intraoperative tissue speci-
mens, making contamination unlikely. Moreover, skin
commensals, including coagulase-negative staphylococci
and especially S. epidermidis, are frequent pathogens of
low-grade orthopedic implants [8, 14–16] due to their
ability to perform biofilms [44]. Lastly, we cannot retro-
spectively enumerate the individual reasons for a delayed
surgery. As simple as it seems, in a retrospective study this
question is very difficult to be answered. The reasons may
vary between lack of operation slots, triage issues, lack of
patient’s and family’s consent, nosocomial fractures occur-
ring during a hospital stay for another reason, availability
of the individual surgeon, week-ends and holidays,
non-availability of the specific osteosynthesis material, or
a panoply of combined reasons. However, we do not think
that the individual reason for delay would have influenced
our findings in this large epidemiological study.
Conclusions
According to our retrospective cohort analysis, a long
pre-surgical hospital stay was not associated with more
prophylaxis-resistant SSIs, in 611 adult patients under-
going orthopedic implant surgery, when compared to
those with prophylaxis-susceptible pathogens. We keep
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our antibiotic perioperative prophylaxis policy as it is,
regardless of the duration of pre-surgical length of hos-
pital stay.
Acknowledgements
We thank the teams of the Laboratory of Bacteriology and the Orthopedic
Service for support.
Funding
None.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
MD, LW, DH, and IU conceived and designed the study. DH and SH were
major contributors in writing and supervising the manuscript. MD, LW, DS
treated most patients and supervised the study. MD and IU performed the
data analysis. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This retrospective study based on four composite databases, which were all
approved by the local research ethics committee. The processing of patients’
personal data was anonymized and complied with local data protection
legislations. As no individual data is published as well as no intervention was
performed to patients, the formal patient consent was waived.
Consent for publication
No applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Orthopedic Surgery Service, Geneva University Hospitals, Geneva,
Switzerland. 2Infection Control Program, Geneva University Hospitals, Geneva,
Switzerland. 3Infectiology, Balgrist University Hospital, Forchstrasse 340, 8008
Zürich, Switzerland.
Received: 20 September 2018 Accepted: 11 October 2018
References
1. Landelle C, Iten A, Uçkay I, Sax H, Camus V, Cohen G, Renzi G, et al. Does
colonization with methicillin-susceptible Staphylococcus aureus protect
against nosocomial acquisition of methicillin-resistant S. aureus? Infect
Control Hosp Epidemiol. 2014;35:527–33.
2. Uçkay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections
in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp
Infect. 2013;84:5–12.
3. Uçkay I, Sax H, Iten A, Camus V, Renzi G, Schrenzel J, et al. Effect of
screening for methicillin-resistant Staphylococcus aureus carriage by
polymerase chain reaction on the duration of unnecessary preemptive
contact isolation. Infect Control Hosp Epidemiol. 2008;29:1077–9.
4. Uçkay I, Harbarth S, Ferry T, Lübbeke A, Emonet S, Hoffmeyer P, et al.
Methicillin-resistance in orthopaedic coagulase-negative staphylococcal
infections. J Hosp Infect. 2011;79:248–53.
5. Uçkay I, Pires D, Agostinho A, Guanziroli N, Öztürk M, Bartolone P, et al.
Enterococci in orthopaedic infections: who is at risk getting infected? J Inf
Secur. 2017;75:309–14.
6. Jamei O, Gjoni S, Zenelaj B, Kressmann B, Belaieff W, Hannouche D, et al.
Which Orthopaedic patients are infected with gram-negative non-
fermenting rods? J Bone Jt Infect. 2017;2:73–6.
7. Agostinho A, Renzi G, Haustein T, Jourdan G, Bonfillon C, Rougemont M, et al.
Epidemiology and acquisition of extended-spectrum beta-lactamase-producing
Enterobacteriaceae in a septic orthopedic ward. SpringerPlus. 2013;2:91.
8. Cuérel C, Abrassart S, Billières J, Andrey D, Suvà D, Dubois-Ferrière V, et al. Clinical
and epidemiological differences between implant-associated and implant-free
orthopaedic infections. Eur J Orthop Surg Traumatol. 2017;27:229–31.
9. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Maureen K,
Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in
surgery. Am J Health Syst Pharm. 2013;70:195–283.
10. WHO Global guidelines for the prevention of surgical site infections. WHO.
In: Geneva; 2016.
11. Parvizi J, Gehrke T, Chen AF. Proceedings of the international consensus
meeting on Periprosthetic joint infection. Bone Joint J. 2013;95-B:1450–2.
12. Courtney PM, Melnic CM, Zimmer Z, Anari J, Lee GC. Addition of
Vancomycin to Cefazolin prophylaxis is associated with acute kidney injury
after primary joint Arthroplasty. Clin Orthop Relat Res. 2015;473:2197–203.
13. Uçkay I, Lübbeke A, Harbarth S, Emonet S, Tovmirzaeva L, Agostinho A, et al.
Low risk despite high endemicity of methicillin-resistant Staphylococcus
aureus infections following elective total joint arthroplasty: a 12-year
experience. Ann Med. 2012;44:360–8.
14. Teterycz D, Ferry T, Lew D, Stern R, Assal M, Hoffmeyer P, et al. Outcome of
orthopedic implant infections due to different staphylococci. Int J Infect Dis.
2010;14:913–8.
15. Al-Mayahi M, Betz M, Müller DA, Stern R, Tahintzi P, Bernard L, et al.
Remission rate of implant-related infections following revision surgery after
fractures. Int Orthop. 2013;37:2253–8.
16. Mohamad M, Uçkay I, Hannouche D, Miozzari H. Particularities of Staphylococcus
lugdunensis in orthopaedic infections. Infect Dis (Lond). 2018;50:223–5.
17. Tan TL, Springer BD, Ruder JA, Ruffolo MR, Chen AF. Is Vancomycin-only
prophylaxis for patients with penicillin allergy associated with increased risk
of infection after Arthroplasty? Clin Orthop Relat Res. 2016;474:1601–6.
18. Gonzalez A, Suvà D, Dunkel N, Nicodème JD, Lomessy A, Lauper N, et al.
Are there clinical variables determining antibiotic prophylaxis-susceptible
versus resistant infection in open fractures? Int Orthop. 2014;38:2323–7.
19. Lübbeke A, Zingg M, Vu D, Miozzari HH, Christofilopoulos P, Uçkay I, et al.
Body mass and weight thresholds for increased prosthetic joint infection
rates after primary total joint arthroplasty. Acta Orthop. 2016;87:132–8.
20. Jugun K, Vaudaux P, Garbino J, Pagani L, Hoffmeyer P, Lew D, et al. The safety
and efficacy of high-dose daptomycin combined with rifampicin for the
treatment of gram-positive osteoarticular infections. Int Orthop. 2013;37:1375–80.
21. Dunkel N, Belaieff W, Assal M, Corni V, Karaca Ş, Lacraz A, et al. Wound
dehiscence and stump infection after lower limb amputation: risk factors
and association with antibiotic use. J Orthop Sci. 2012;17:588–94.
22. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for
prevention of surgical site infection, 1999. Centers for Disease Control and
Prevention (CDC) Hospital Infection Control Practices Advisory Committee.
Am J Infect Control. 1999;27:97–132.
23. Uçkay I, Lübbeke A, Emonet S, Tovmirzaeva L, Stern R, Ferry T, et al. Low
incidence of haematogenous seeding to total hip and knee prostheses in
patients with remote infections. J Inf Secur. 2009;59:337–45.
24. Sendi P, Christensson B, Uçkay I, Trampuz A, Achermann Y, Boggian K, et al.
Group B streptococcus in prosthetic hip and knee joint-associated
infections. J Hosp Infect. 2011;79:64–9.
25. Performance Standards for Antimicrobial Susceptibility Testing; 17th
Informational Supplement. Clinical and Laboratory Standards Institute.
Pennsylvania; USA: Wayne; 2007.
26. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for
interpretation of MICs. Version. 2014:4 http://www.eucast.org/clinical_breakpoints.
27. Billières J, Uçkay I, Faundez A, Douissard J, Kuczma P, Suvà D, et al.
Variables associated with remission in spinal surgical site infections. J
Spine Surg. 2016;2:128–34.
28. Lebowitz D, Kressmann B, Gjoni S, Zenelaj B, Grosgurin O, Marti C, et al. Clinical
features of anaerobic orthopaedic infections. Infect Dis (Lond). 2017;49:137–40.
29. Al-Mayahi M, Cian A, Lipsky BA, Suvà D, Müller C, Landelle C, et al.
Administration of antibiotic agents before intraoperative sampling in
orthopedic infections alters culture results. J Inf Secur. 2015;71:518–25.
30. Baraboutis IG, Tsagalou EP, Papakonstantinou I, Marangos MN, Gogos C,
Skoutelis AT, et al. Length of exposure to the hospital environment is more
important than antibiotic exposure in healthcare associated infections by
methicillin-resistant Staphylococcus aureus: a comparative study. Braz J Infect
Dis. 2011;15:426–35.
Davat et al. Antimicrobial Resistance and Infection Control           (2018) 7:131 Page 6 of 7
31. Nadeem RD, Akhtar M, Cheema OI, Hashmi AR, Nadeem MJ, Nadeem A.
Antibiotic prophylaxis in hip surgery: a comparison of two vs. three doses of
cefuroxime. J Pak Med Assoc. 2015;65:136–41.
32. Engesaeter LB, Lie SA, Espehaug B, Furnes O, Vollset SE, Havelin LI.
Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic
prophylaxis systemically and in bone cement on the revision rate of 22,170
primary hip replacements followed 0-14 years in the Norwegian
Arthroplasty register. Acta Orthop Scand. 2003;74:644–51.
33. OʼToole RV, Joshi M, Carlini AR, Murray CK, Allen LE, Scharfstein DO, et al.
Local antibiotic therapy to reduce infection after operative treatment of
fractures at high risk of infection: a multicenter, randomized, controlled trial
(VANCO study). J Orthop Trauma. 2017;31:18–24.
34. Westberg M, Frihagen F, Brun OC, Figved W, Grøgaard B, Valland H, et al.
Effectiveness of gentamicin-containing collagen sponges for prevention of
surgical site infection after hip arthroplasty: a multicenter randomized trial.
Clin Infect Dis. 2015;60:1752–9.
35. Chotai S, Wright PW, Hale AT, Jones WA, McGirt MJ, Patt JC, et al. Does
Intrawound Vancomycin application during spine surgery create
Vancomycin-resistant organism? Neurosurgery. 2017;80:746–53.
36. Burger JR, Hansen BJ, Leary EV, Aggarwal A, Keeney JA. Dual-agent
antibiotic prophylaxis using a single preoperative Vancomycin dose
effectively reduces prosthetic joint infection rates with minimal renal
toxicity risk. J Arthroplast. 2018;33:213–8.
37. Bosco JA, Tejada PRR, Catanzano AJ, Stachel AG, Phillips MS. Expanded
gram-negative antimicrobial prophylaxis reduces surgical site infections in
hip Arthroplasty. J Arthroplast. 2016;31:616–21.
38. Bell S, Davey P, Nathwani D, Marwick C, Vadiveloo T, Sneddon J, et al. Risk of AKI
with gentamicin as surgical prophylaxis. J Am Soc Nephrol. 2014;25:2625–32.
39. Branch-Elliman W, Ripollone JE, O'Brien WJ, Itani KMF, Schweizer ML,
Perencevich E, et al. Risk of surgical site infection, acute kidney injury, and
Clostridium difficile infection following antibiotic prophylaxis with
vancomycin plus a beta-lactam versus either drug alone: a national
propensity-score-adjusted retrospective cohort study. PLoS Med. 2017;14:
1002340.
40. Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, et al. A
systematic review and economic model of switching from non-
glycopeptide to glycopeptide antibiotic prophylaxis for surgery. Health
Technol Assess. 2008;12:1–147.
41. Mini E, Nobili S, Periti P. Methicillin-resistant staphylococci in clean surgery.
Is there a role for prophylaxis? Drugs. 1997;54:39–52.
42. Crawford T, Rodvold KA, Solomkin JS. Vancomycin for surgical prophylaxis?
Clin Infect Dis. 2012;54:1474–9.
43. Walker H, Patton A, Bayne G, Marwick C, Sneddon J, Davey P, et al.
Reduction in post-operative acute kidney injury following a change in
antibiotic prophylaxis policy for orthopaedic surgery: an observational study.
J Antimicrob Chemother. 2016;71:2598–605.
44. Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. Foreign body
infections due to Staphylococcus epidermidis. Ann Med. 2008;14:1–11.
Davat et al. Antimicrobial Resistance and Infection Control           (2018) 7:131 Page 7 of 7
